Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123876 | 0.76 | CA2 (0.35) | — | |
| SCHEMBL25520674 | 0.76 | USP2 (0.48) | USP2TSHRKDM4EALDH1A1LMNA | |
| Ethane Dimethane Sulfonate SCHEMBL1336145 | 0.75 | USP2 (0.75) | USP2TSHRKDM4EALDH1A1LMNA | |
| Ethane Dimethane Sulfonate SCHEMBL17022719 | 0.73 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| Ethane Dimethane Sulfonate SCHEMBL4148513 | 0.70 | USP2 (0.67) | USP2TSHRKDM4EALDH1A1LMNA | |
| Ethane Dimethane Sulfonate SCHEMBL4154177 | 0.70 | USP2 (0.67) | USP2TSHRKDM4EALDH1A1LMNA | |
| Ethane Dimethane Sulfonate SCHEMBL4140371 | 0.70 | USP2 (0.67) | USP2TSHRKDM4EALDH1A1LMNA | |
| Ethane Dimethane Sulfonate SCHEMBL4149477 | 0.70 | USP2 (0.67) | USP2TSHRKDM4EALDH1A1LMNA | |
| Ethane Dimethane Sulfonate SCHEMBL4143911 | 0.70 | USP2 (0.67) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL2165944 | 0.70 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145771-A1 | N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| CN-111164069-A | N- (3- (2- (4-chlorophenoxy) acetamido) bicyclo [1.1.1] pent-1-yl) -2-cyclobutane-1-carboxamide derivatives and related compounds as ATF4 inhibitors for the treatment of cancer and other diseases | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-3649106-A1 | N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1]PENTAN-1-YL)-2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019008506-A1 | N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1]PENTAN-1-YL)-2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145771-A1 | N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES | ATF4, EIF2B1, EIF4A1 | USP2 1690/4885TSHR 2530/4885KDM4E 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.